

Botox[®] (onabotulinumtoxinA) Injectable Medication Precertification Request

Page 1 of 3

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY:711)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate: Start of				,			
∟ Continu Precertification Requested E	lation of therapy, Date of	r last treatment	<u>/ /</u> Phone:		Fax:		
A. PATIENT INFORMATION	Jy		1 11011e.		1 ax		
First Name:		Last Name:			DOB:		
Address:		1	City:		1	ZIP:	
Home Phone:	Work Phone:	+	Cell Phone:		Email:		
Patient Current Weight:				Δllergies:			
B. INSURANCE INFORMATION		it rieightinches	5 OI CITIS	Allergies.			
Aetna Member ID #:		Does nationt have oth	er coverage?	□ Ves □ Ne			
Group #:		Does patient have other coverage?					
Insured:		Insured:		<u> </u>			
Medicare: ☐ Yes ☐ No If y	es, provide ID #:	Me	dicaid: Yes	☐ No If yes, provi	de ID #:		
C. PRESCRIBER INFORMAT	ION						
First Name:		Last Name:		(Check Or	ne):	D.O. 🗌 N.P. 🗌 P.A.	
Address:			City:		State:	ZIP:	
Phone:	ax:	St Lic #:	NPI#:	DEA #:		UPIN:	
Provider Email:		Office Contact Name:		'	Phone:		
Specialty (Check one): Der	matologist	st Orthopedist	Otolaryngologist	☐ Physiatrist ☐	Other:	-	
D. DISPENSING PROVIDER/		•	, , , ,				
☐ Outpatient Infusion Center Center Name: ☐ Home Infusion Center Agency Name: ☐ Administration code(s) (CP' Address:	Phone:		Name: Address: Phone:	s Office	Fax:		
E. PRODUCT INFORMATION							
Request is for: Botox (onabo							
**Please note - requests over 40 F. DIAGNOSIS INFORMATIO				applicable			
Primary ICD Code:					D Code:		
G. CLINICAL INFORMATION							
For All Requests (clinical docu			od iii ito <u>ortaroty</u> rot		Heteletere.		
			ıkles or uncorrected	l congenital strabisr	nus and no binoc	cular fusion)?	
 Yes ☐ No Is therapy prescribed for cosmetic purposes (e.g., treatment of wrinkles or uncorrected congenital strabismus and no binocular fusion)? Achalasia ☐ Yes ☐ No Has the patient tried and failed or is a poor candidate for conventional therapy such as pneumatic dilation and surgical myotomy? ☐ Yes ☐ No Will the requested drug be prescribed by or in consultation with a gastroenterologist, proctologist, or colorectal surgeon? 							
Blepharospasm							
Yes No Has the patient been diagnosed with blepharospasm, including blepharospasm associated with dystonia, benign essential blepharospasm or VII nerve disorder?							
 ☐ Yes ☐ No Will the requested drug be prescribed by or in consultation with a neurologist or ophthalmologist? ☐ Cervical dystonia (e.g., torticollis) 							
☐ Yes ☐ No Prior to initia ☐ Yes ☐ No Will the requ	ating therapy with the reque						
☐ Chronic anal fissure							
Yes No Has the patient failed to respond to first line therapy for chronic anal fissures such as topical calcium channel blockers or topical nitrates? Yes No Will the requested drug be prescribed by or in consultation with a gastroenterologist, proctologist, or colorectal surgeon?							

Continued on next page



Botox[®] (onabotulinumtoxinA) Injectable Medication Precertification Request

Page 2 of 3

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY:711)

FAX: 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB					
G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.								
☐ Chronic migraine prophylaxis								
Prior to initiating therapy, how many days per month does (did) the patient experience headaches? ☐ 15 days or more ☐ Less than 15 days ☐ Yes ☐ No Do (did) the patient's headaches last 4 hours or longer on at least 8 days per month?								
` , .	· · · · · · · · · · · · · · · · · · ·	• •	at least 2 of the following eleases:					
Yes No Has the patient completed an adequate trial of 2 oral migraine preventative therapies coming from at least 2 of the following classes: antidepressants (e.g., amitriptyline, venlafaxine), or antiepileptic drugs (AEDs) (e.g., divalproex sodium, topiramate, valproate sodium), or beta-adrenergic blocking agents (e.g., metoprolol, propranolol, timolol, atenolol, nadolol)?								
Yes No Does the patient have a contraindication to any of the following classes: antidepressants (e.g., amitriptyline, venlafaxine), or antiepileptic drugs (AEDs) (e.g., divalproex sodium, topiramate, valproate sodium), or beta-adrenergic blocking agents (e.g., metoprolol, propranolol, timolol, atenolol, nadolol)?								
	→ Please indicate the number of classes the patient has a contraindication to: □ One class or □ Two classes or more							
─────────────────────────────────────	e the number of classes the patient had an ac		classes or more					
	e how many days was the trial of each drug:							
☐ Yes ☐ No Does the patient have signs and symptoms consistent with chronic migraine diagnostic criteria as defined by the International Headache Society (IHS)?								
	ed drug be prescribed by or in consultation w	rith a neurologist, pain specialist, or ph	ysiatrist?					
Essential tremor								
	ed drug be prescribed by or in consultation w	rith a neurologist, pain specialist, or ph	ysiatrist?					
Excessive salivation (chronic s								
	fractory to pharmacotherapy (e.g., anticholine							
	ed drug be prescribed by or in consultation w	ith a neurologist or otolaryngologist?						
☐ Facial myokymia								
	ed drug be prescribed by or in consultation w	ith a neurologist, orthopedist, otolaryn	gologist, or physiatrist?					
☐ First bite syndrome								
	failed to experience relief from analgesics, ar							
	ed drug be prescribed by or in consultation w	rith a neurologist or oncologist?						
☐ Focal hand dystonia								
	ed drug be prescribed by or in consultation w	rith a neurologist, orthopedist, otolaryn	gologist, or physiatrist?					
☐ Hemifacial spasm								
	ed drug be prescribed by or in consultation w	rith a neurologist, orthopedist, otolaryn	gologist, or physiatrist?					
Hirschsprung disease with internal sphincter achalasia								
	undergone an endorectal pull through to trea	t the Hirschsprung disease with interna	al sphincter achalasia?					
Yes No Is the patient ref								
	ed drug be prescribed by or in consultation w	rith a gastroenterologist, proctologist, o	r colorectal surgeon?					
Limb spasticity								
	owing applies to the patient: Upper limb sp							
(including focal	t have a primary diagnosis of upper or lower spasticity or equinus gait due to cerebral pals	sy)?						
	ed drug be prescribed by or in consultation w	rith a neurologist, orthopedist, otolaryn	gologist, or physiatrist?					
☐ Myofascial pain syndrome								
	owing treatments has the patient tried and fail							
☐ Physical therapy ☐ Injection of local anesthetics into trigger points ☐ Injection of corticosteroids into trigger points								
Please indicate how many treatn								
Yes No Will the requested drug be prescribed by or in consultation with a neurologist, orthopedist, otolaryngologist, or physiatrist?								
☐ Orofacial tardive dyskinesia								
or tetrabenazine	•		•					
	ed drug be prescribed by or in consultation w	rith a neurologist, pain specialist, or ph	ysiatrist?					
Oromandibular dystonia								
☐ Yes ☐ No Will the requeste	ed drug be prescribed by or in consultation w	rith a neurologist or otolaryngologist?						

Continued on next page



Botox® (onabotulinumtoxinA) Injectable **Medication Precertification Request**

Page 3 of 3

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY:711)

FAX: 1-888-267-3277

For Medicare Advantage Part B:

(All fields must be completed and legible for precertification review.) Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB				
G. CLINICAL INFORMATION (continued	d) – Required clinical information must be co	ompleted in its <u>entirety</u> for all prec	ertification requests.				
☐ Overactive bladder with urinary incont	inence						
☐ Yes ☐ No Prior to initiating therapy with the requested drug, along with urinary incontinence, does (did) the patient experience urgency and frequency?							
l <u> </u>	☐ Yes ☐ No Has the patient tried and failed behavioral therapy?						
☐ Yes ☐ No Has the patient had an i	No Has the patient had an inadequate response or experienced intolerance to at least 2 agents from either of the following classes?						
Anticholinergic medications (e.g., Vesicare [solifenacin], Enablex [darifenacin], Toviaz [fesoterodine], Detrol/Detrol LA [tolterodine], Sanctura/Sanctura XR [trospium], Ditropan XL [oxybutynin]							
	☐ Beta-3 adrenergic agonist (e.g., Myrbetriq [mirabegron], Gemtesa [vibegron])						
☐ Yes ☐ No Will the requested drug be prescribed by or in consultation with neurologist, urologist, or gynecologist?							
☐ Painful bruxism	·						
☐ Yes ☐ No Did the patient try and h	ave an inadequate response to a night guard?						
☐ Yes ☐ No Did the patient have an i	inadequate response to pharmacotherapy suc	h as diazepam?					
☐ Yes ☐ No Will the requested drug	be prescribed by or in consultation with a neur	ologist or otolaryngologist?					
☐ Palatal myoclonus							
☐ Yes ☐ No Prior to initiating therapy	with the requested drug, does (did) the patien	nt have disabling symptoms (e.g., in	trusive clicking tinnitus)?				
☐ Yes ☐ No Did the patient have an i	Yes No Did the patient have an inadequate response to clonazepam, lamotrigine, carbamazepine, or valproate?						
☐ Yes ☐ No Will the requested drug l	be prescribed by or in consultation with a neur	ologist or otolaryngologist?					
☐ Primary axillary, palmar, and gustatory (Frey's syndrome) hyperhidrosis							
☐ Yes ☐ No Has significant disruption	n of professional and/or social life occurred be	cause of excessive sweating?					
☐ Yes ☐ No Has the patient tried top	ical aluminum chloride or other extra-strength	antiperspirants?					
Yes 🗌 No Was the topical aluminum chloride or other extra-strength antiperspirant ineffective or resulted in a severe rash?							
☐ Yes ☐ No Will the requested drug be prescribed by or in consultation with a neurologist, internist, or dermatologist?							
☐ Spasmodic dysphonia (laryngeal dystonia)							
☐ Yes ☐ No Will the requested drug	be prescribed by or in consultation with a neur	ologist or otolaryngologist?					
☐ Strabismus							
	Yes No Is interference with the patient's normal visual system development is likely to occur? Note: Strabismus repair is considered cosmetic in adults with uncorrected congenital strabismus and no binocular fusion.						
☐ Yes ☐ No Is the patient likely to ha	ve spontaneous recovery?						
☐ Yes ☐ No Will the requested drug	be prescribed by or in consultation with a neur	ologist or ophthalmologist?					
☐ Urinary incontinence associated with a	neurologic condition (e.g., spinal cord injury	, multiple sclerosis)					
☐ Yes ☐ No Has the patient tried and	d failed behavioral therapy?						
☐ Yes ☐ No Has the patient had an i	nadequate response or experienced intolerand	ce to 1 agent from either of the follow	ving classes?				
I	lications (e.g., Vesicare [solifenacin], Enablex XR [trospium], Ditropan XL [oxybutynin]	[darifenacin], Toviaz [fesoterodine],	Detrol/Detrol LA [tolterodine],				
☐ Beta-3 adrenergic a	agonist (e.g., Myrbetriq [mirabegron])						
☐ Yes ☐ No Will the requested drug	be prescribed by or in consultation with a neur	ologist, urologist, or gynecologist?					
For All Continuation Requests (clinical do	cumentation required):						
☐ Yes ☐ No Was the requested drug effe	ective for treating the diagnosis or condition?						
☐ Chronic migraine prophylaxis only							
Yes No Has the patient achieved or maintained a reduction in monthly headache frequency since starting the requested drug therapy?							
☐ Yes ☐ No Will the requested drug	be prescribed by or in consultation with a neur	ologist, pain specialist, or physiatris	t?				
H. ACKNOWLEDGEMENT							
	uired):		Date://				
Any person who knowingly files a request	t for authorization of coverage of a medical erially false information or conceals materia	procedure or service with the inte	ent to injure, defraud or deceive				

insurance act, which is a crime and subjects such person to criminal and civil penalties. The plan may request additional information or clarification, if needed, to evaluate requests.